Advances in the early detection of ovarian carcinoma

Journal of Reproductive Medicine for the Obstetrician and Gynecologist

Volumn 50, Issue 6, 2005, Pages 447-453

  Garner, Elizabeth I O ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Mass screening; Ovarian cancer; Ovarian carcinoma

Indexed keywords

BIOLOGICAL MARKER; CA 125 ANTIGEN; COMPLEMENTARY DNA;

CANCER DIAGNOSIS; CANCER SCREENING; CANCER STAGING; CONFERENCE PAPER; DNA DETERMINATION; DNA MICROARRAY; ECHOGRAPHY; GENE EXPRESSION; HIGH RISK POPULATION; HUMAN; OVARY CARCINOMA; PHYSICAL EXAMINATION; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEOMICS; RNA ANALYSIS; SENSITIVITY AND SPECIFICITY;

CA-125 ANTIGEN; FEMALE; HUMANS; MASS SCREENING; OVARIAN NEOPLASMS; PHYSICAL EXAMINATION; PROTEOMICS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL; ULTRASONOGRAPHY;

EID: 20844444161     PISSN: 00247758     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (37)

1. Berek JS: Epithelial ovarian cancer. In Practical Gynecologic Oncology. Edited by JS Berek, NF Hacker. Philadelphia, Lippincott Williams and Wilkins, 2000, p 457
2. Gusberg SB, Deligdisch L: Ovarian dysplasia: A study of identical twins. Cancer 1984;54:1-4
3. Dyck HG, Hamilton TC, Godwin AK, et al: Autonomy of the epithelial phenotype in human ovarian surface epithelium: Changes with neoplastic progression and with a family history of ovarian cancer. Int J Cancer 1996;69:429-436
4. Mittal KR, Zeleniuch-Jacquotte A, Cooper JL, et al: Contralateral ovary in unilateral ovarian carcinoma: A search for preneoplastic lesions. Int J Gynecol Pathol 1993;12:59-63
5. Lu KH, Garber JE, Cramer DW, et al: Occult ovarian tumors in women with brca1 or brca2 mutations undergoing prophylactic oophorectomy. J Clin Oncol 2000;18:2728-2732
6. Salazar H, Godwin AK, Daly MB, et al: Microscopic benign and invasive malignant neoplasms and a cancer-prone phenotype in prophylactic oophorectomies. J Natl Cancer Inst 1996;88:1810-1820
7. Carlson KJ, Skates SJ, Singer DE: Screening for ovarian cancer. Ann Intern Med 1994;121:124-132
8. Galen RS, Gambino SR: Beyond Normality: The Predictive Value and Efficiency of Medical Diagnosis. New York, John Wiley and Sons, 1975
9. ACOG Committee on Gynecologic Practice: Routine Cancer Screening. Washington, DC, American College of Obstetricians and Gynecologists, 1997
10. Macfarlene C, Sturgis MC, Fetherman FC: Results of an experiment in the control of cancer of the female pelvic organs in report of a fifteen year research. Am J Obstet Gynecol 1955;69:294-298
11. Jacobs I, Bast RC Jr: The CA-125 tumour-associated antigen: A review of the literature. Hum Reprod 1989;4:1-12
12. Zurawski VR Jr, Knapp RC, Einhorn N, et al: An initial analysis of preoperative serum CA-125 levels in patients with early-stage ovarian carcinoma. Gynecol Oncol 1988;30: 7-14
13. Jeyarajah AR, Ind TE, Skates S, et al: Serum ca125 elevation and risk of clinical detection of cancer in asymptomatic post-menopausal women. Cancer 1999;85:2068-2072
14. Jacobs IJ, Skates S, Davies AP, et al: Risk of diagnosis of ovarian cancer after raised serum CA-125 concentration: A prospective cohort study. BMJ 1996;313:1355-1358
15. Jeyarajah AR, Ind TE, MacDonald N, et al: Increased mortality in postmenopausal women with serum ca125 elevation. Gynecol Oncol 1999;73:242-246
16. Einhorn N, Sjovall K, Knapp RC, et al: Prospective evaluation of serum CA-125 levels for early detection of ovarian cancer. Obstet Gynecol 1992;80:14-18
17. Schwartz PE: The role of tumor markers in the preoperative diagnosis of ovarian cysts. Clin Obstet Gynecol 1993;36:384-394
18. Skates SJ, Xu FJ, Yu YH, et al: Toward an optimal algorithm for ovarian cancer screening with longitudinal tumor markers. Cancer 1995;76:2004-2010
19. Campbell S, Royston P, Bhan V, et al: Novel screening strategies for early ovarian cancer by transabdominal ultrasonography. Br J Obstet Gynaecol 1990;97:304-311
20. van Nagell JR Jr, Higgins RV, Donaldson ES, et al: Transvaginal sonography as a screening method for ovarian cancer: A report of the first 1000 cases screened. Cancer 1990;65: 573-577
21. van Nagell JR Jr, DePriest PD, Gallion HH, et al: Ovarian cancer screening. Cancer 1993;71:1523-1528
22. van Nagell JR Jr, DePriest PD, Reedy MB, et al: The efficacy of transvaginal sonographic screening in asymptomatic women at risk for ovarian cancer. Gynecol Oncol 2000;77: 350-356
23. Bourne T, Campbell S, Steer C, et al: Transvaginal colour flow imaging: A possible new screening technique for ovarian cancer. BMJ 1989;299:1367-1370
24. Kurjak A, Zalud I, Alfirevic Z: Evaluation of adnexal masses with transvaginal color ultrasound. J Ultrasound Med 1991; 10:295-297
25. Karlan BY, Raffel LJ, Crvenkovic G, et al: A multidisciplinary approach to the early detection of ovarian carcinoma: Rationale, protocol design, and early results. Am J Obstet Gynecol 1993;169:494-501
26. Jacobs I, Stabile I, Bridges J, et al: Multimodal approach to screening for ovarian cancer. Lancet 1988;1:268-271
27. Jacobs I, Davies AP, Bridges J, et al: Prevalence screening for ovarian cancer in postmenopausal women by CA-125 measurement and ultrasonography. BMJ 1993;306:1030-1034
28. Kramer BS, Gohagan J, Prorok PC, et al: A National Cancer Institute sponsored screening trial for prostatic, lung, colorectal, and ovarian cancers. Cancer 1993;71:589-593
29. Woolas RP, Xu FJ, Jacobs IJ, et al: Elevation of multiple serum markers in patients with stage I ovarian cancer. J Natl Cancer Inst 1993;85:1748-1751
30. Woolas R, Xu FJ, Jacobs I: Serum levels of CA-125, m-csf and ovx1 in stage I and preclinical ovarian cancer. Proc Annual Meeting of American Society of Clinical Oncology, March 1993
31. Herbst AL: The epidemiology of ovarian carcinoma and the current status of tumor markers to detect disease. Am J Obstet Gynecol 1994;170:1099-1105; discussion 1105-1097
32. Bandera CA, Ye B, Mok SC: New technologies for the identification of markers for early detection of ovarian cancer. Curr Opin Obstet Gynecol 2003;15:51-55
33. Kim JH, Skates SJ, Uede T, et al: Osteopontin as a potential diagnostic biomarker for ovarian cancer. JAMA 2002;287: 1671-1679
34. Mok SC, Chao J, Skates S, et al: Prostasin, a potential serum marker for ovarian cancer: Identification through microarray technology. J Natl Cancer Inst 2001;93:1458-1464
35. Kim JH, Herlyn D, Wong KK, et al: Identification of epithelial cell adhesion molecule autoantibody in patients with ovarian cancer. Clin Cancer Res 2003;9:4782-4791
36. Petricoin EF, Ardekani AM, Hitt BA, et al: Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002; 359:572-577
37. Ye B, Cramer DW, Skates SJ, et al: Haptoglobin-alpha subunit as potential serum biomarker in ovarian cancer: Identification and characterization using proteomic profiling and mass spectrometry. Clin Cancer Res 2003;9:2904-2911